Aarti Drugs Limited (AARTIDRUGS) - Total Assets
Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) holds total assets worth Rs26.12 Billion INR (≈ $282.51 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Aarti Drugs Limited investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Aarti Drugs Limited - Total Assets Trend (2006–2025)
This chart illustrates how Aarti Drugs Limited's total assets have evolved over time, based on quarterly financial data. Explore Aarti Drugs Limited (AARTIDRUGS) investment intensity to see how much of total assets are deployed in long-term investments.
Aarti Drugs Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Aarti Drugs Limited's total assets of Rs26.12 Billion consist of 52.0% current assets and 48.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.3% |
| Accounts Receivable | Rs7.52 Billion | 29.2% |
| Inventory | Rs4.73 Billion | 18.4% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs71.50 Million | 0.3% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Aarti Drugs Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AARTIDRUGS market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aarti Drugs Limited's current assets represent 52.0% of total assets in 2025, an increase from 49.1% in 2006.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2025, down from 0.5% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 29.2% of total assets.
Aarti Drugs Limited Competitors by Total Assets
Key competitors of Aarti Drugs Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Aarti Drugs Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.68 | 1.61 | 1.64 |
| Quick Ratio | 1.08 | 1.01 | 1.08 |
| Cash Ratio | 0.01 | 0.02 | 0.00 |
| Working Capital | Rs5.30 Billion | Rs4.75 Billion | Rs4.09 Billion |
Aarti Drugs Limited - Advanced Valuation Insights
This section examines the relationship between Aarti Drugs Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.31 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 5.9% |
| Total Assets | Rs25.75 Billion |
| Market Capitalization | $365.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aarti Drugs Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Aarti Drugs Limited's assets grew by 5.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Aarti Drugs Limited (2006–2025)
The table below shows the annual total assets of Aarti Drugs Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs25.75 Billion ≈ $278.44 Million |
+5.85% |
| 2024-03-31 | Rs24.32 Billion ≈ $263.05 Million |
+0.45% |
| 2023-03-31 | Rs24.21 Billion ≈ $261.87 Million |
+9.67% |
| 2022-03-31 | Rs22.08 Billion ≈ $238.78 Million |
+25.02% |
| 2021-03-31 | Rs17.66 Billion ≈ $190.99 Million |
+12.02% |
| 2020-03-31 | Rs15.77 Billion ≈ $170.49 Million |
+7.77% |
| 2019-03-31 | Rs14.63 Billion ≈ $158.20 Million |
+5.40% |
| 2018-03-31 | Rs13.88 Billion ≈ $150.10 Million |
+17.88% |
| 2017-03-31 | Rs11.77 Billion ≈ $127.33 Million |
+6.82% |
| 2016-03-31 | Rs11.02 Billion ≈ $119.20 Million |
+10.01% |
| 2015-03-31 | Rs10.02 Billion ≈ $108.36 Million |
+17.91% |
| 2014-03-31 | Rs8.50 Billion ≈ $91.90 Million |
+18.07% |
| 2013-03-31 | Rs7.20 Billion ≈ $77.83 Million |
+17.48% |
| 2012-03-31 | Rs6.13 Billion ≈ $66.25 Million |
+17.03% |
| 2011-03-31 | Rs5.23 Billion ≈ $56.61 Million |
+24.91% |
| 2010-03-31 | Rs4.19 Billion ≈ $45.32 Million |
+3.93% |
| 2009-03-31 | Rs4.03 Billion ≈ $43.61 Million |
-3.22% |
| 2008-03-31 | Rs4.17 Billion ≈ $45.06 Million |
+13.74% |
| 2007-03-31 | Rs3.66 Billion ≈ $39.62 Million |
-0.31% |
| 2006-03-31 | Rs3.67 Billion ≈ $39.74 Million |
-- |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more